Vivos Therapeutics Business Summary

Vivos Therapeutics, Inc. (VVOS) is a medical technology company specializing in non-invasive, non-surgical treatments for obstructive sleep apnea (OSA) and snoring. The company generates revenue through two primary business segments: product sales and service revenue. Product revenue is derived from its proprietary Complete Airway Repositioning and/or Expansion (CARE) oral appliances, including the DNA and mRNA devices, which are the first and only oral appliances FDA-cleared to treat all levels of OSA severity in adults. Service revenue is driven by its vertically integrated medical practice model, following the 2025 acquisition of The Sleep Center of Nevada (SCN), and strategic alliances with sleep-focused medical practices. This shift marks a transition away from its legacy Vivos Integrated Provider (VIP) enrollment fee model toward a direct-to-patient clinical service and device distribution strategy. Vivos competes directly with CPAP market leader ResMed, implantable neurostimulation provider Inspire Medical Systems, and precision oral appliance manufacturer ProSomnus. It occupies a unique market niche as a permanent anatomical corrective solution rather than a lifetime palliative therapy, positioning itself as a less intrusive alternative to surgical implants and a more compliant-friendly option than CPAP machines. The company was co-founded by Chairman and CEO R. Kirk Huntsman, a serial entrepreneur who previously scaled DentalOne Partners into a leading national dental service organization, and Susan McCullough, who serves as Executive Vice President of Operations with over 30 years of dental industry experience. The executive team is further strengthened by CFO Brad Amman, who brings a background in financial leadership from LifeVantage and CereScan, and Michael E. Bruhn, appointed in July 2025 as EVP of Business Operations Integration to oversee the company's clinical expansion. The Board of Directors includes notable members such as Leonard Sokolow and recently appointed independent director Gregg C. E. Johnson (effective February 2026), a legal and capital markets veteran. Vivos has attracted institutional backing from investors such as Avondale Capital, LP, which provided significant funding in late 2025, as well as Armistice Capital and The Vanguard Group.